ATE107513T1 - Stabilisierte formulierungen mit hydrohoben proteinen. - Google Patents

Stabilisierte formulierungen mit hydrohoben proteinen.

Info

Publication number
ATE107513T1
ATE107513T1 AT89123384T AT89123384T ATE107513T1 AT E107513 T1 ATE107513 T1 AT E107513T1 AT 89123384 T AT89123384 T AT 89123384T AT 89123384 T AT89123384 T AT 89123384T AT E107513 T1 ATE107513 T1 AT E107513T1
Authority
AT
Austria
Prior art keywords
hydrobic
proteins
stabilized formulations
formulations
disclosed
Prior art date
Application number
AT89123384T
Other languages
English (en)
Inventor
Thomas C Boone
William C Kenney
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23093007&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE107513(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE107513T1 publication Critical patent/ATE107513T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT89123384T 1988-12-16 1989-12-18 Stabilisierte formulierungen mit hydrohoben proteinen. ATE107513T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/285,159 US5104651A (en) 1988-12-16 1988-12-16 Stabilized hydrophobic protein formulations of g-csf

Publications (1)

Publication Number Publication Date
ATE107513T1 true ATE107513T1 (de) 1994-07-15

Family

ID=23093007

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89123384T ATE107513T1 (de) 1988-12-16 1989-12-18 Stabilisierte formulierungen mit hydrohoben proteinen.

Country Status (9)

Country Link
US (1) US5104651A (de)
EP (1) EP0373679B1 (de)
JP (1) JP2888969B2 (de)
AT (1) ATE107513T1 (de)
AU (1) AU621695B2 (de)
CA (1) CA2005143C (de)
DE (1) DE68916385T2 (de)
ES (1) ES2055001T3 (de)
WO (1) WO1990006762A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5847086A (en) * 1991-06-20 1998-12-08 Centeon L.L.C. Therapeutic fragments of von Willebrand factor
MX9203011A (es) * 1991-06-20 1993-08-01 Rhone Poulenc Rorer Int Procedimiento para preparar una solucion acuosa de fragmento de factor de von willebrand alterado con cisteina y solucion terapeutica fundida mediante el mismo
IT1254359B (it) * 1992-05-11 1995-09-14 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti il-6
EP0582932A1 (de) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutisches System zur parenteralen Verabreichung von hämatopoetischen Wachstumsfaktoren
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
CA2092271C (en) * 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
WO1995023862A1 (en) * 1994-03-04 1995-09-08 Ludwig Institute For Cancer Research Animals with targeted gene disruption
USRE38424E1 (en) 1994-11-21 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Method for treating taxol side-effects with G-CSF
DE69620877T2 (de) * 1995-02-06 2002-12-12 Genetics Institute, Inc. Arzneimittelformulierungen für il-12
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
US6355243B1 (en) * 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
DK1129720T3 (da) 2000-02-29 2004-09-27 Pfizer Prod Inc Stabiliseret granulocyt-kolonistimulerende faktor
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
HU228583B1 (en) * 2000-11-07 2013-04-29 Novartis Vaccines & Diagnostic Stabilized interferon compositions
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
IL159524A0 (en) * 2001-07-11 2004-06-01 Maxygen Holdings Ltd G-csf conjugates
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7173003B2 (en) * 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
MXPA04012496A (es) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
US7273921B2 (en) * 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
AU2004221824B2 (en) * 2003-03-14 2009-08-27 Ratiopharm Gmbh Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
JP2007523630A (ja) * 2003-05-09 2007-08-23 ネオス テクノロジーズ インコーポレイテッド ヒト成長ホルモングリコシル化突然変異体の組成と調合法
US9005625B2 (en) * 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
EP2198876B1 (de) * 2003-10-24 2012-12-05 Nora Therapeutics, Inc. Verfahren zur Reduzierung der Wahrscheinlichkeit des Implantationsversagens bei einer Person
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20070254834A1 (en) * 2003-11-24 2007-11-01 Defrees Shawn Glycopegylated Erythropoietin
US8633157B2 (en) * 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
MXPA06006029A (es) * 2003-12-03 2006-08-23 Neose Technologies Inc Factor de estimulacion de colonias de granulocitos modificado por glicopolietilenglicol.
WO2005056760A2 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
ES2560657T3 (es) * 2004-01-08 2016-02-22 Ratiopharm Gmbh Glicosilación con unión en O de péptidos G-CSF
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
US20090292110A1 (en) * 2004-07-23 2009-11-26 Defrees Shawn Enzymatic modification of glycopeptides
EP1799249A2 (de) * 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegyliertes interferon alpha
PL2586456T3 (pl) 2004-10-29 2016-07-29 Ratiopharm Gmbh Remodeling i glikopegilacja czynnika wzrostu fibroblastów (FGF)
EP1817047B1 (de) 2004-11-05 2012-02-08 Northwestern University Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen
US9029331B2 (en) * 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (de) 2005-04-08 2010-03-31 Biogenerix Ag Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons
EP1891231A4 (de) * 2005-05-25 2011-06-22 Novo Nordisk As Glykopegylierter faktor ix
US20110003744A1 (en) * 2005-05-25 2011-01-06 Novo Nordisk A/S Glycopegylated Erythropoietin Formulations
US7381805B2 (en) 2005-06-01 2008-06-03 Maxygen Holdings, Ltd. Compositions comprising mixtures of positional PEG isomers of PEGylated G-CSF
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
KR100735784B1 (ko) * 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
BRPI0614839A2 (pt) * 2005-08-19 2009-05-19 Neose Technologies Inc fator vii e fator viia glicopeguilados
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
RU2322452C2 (ru) * 2006-03-27 2008-04-20 Михаил Николаевич Смирнов Иммуномодулирующая композиция
US20080248959A1 (en) * 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
MX2009003470A (es) * 2006-10-04 2009-04-14 Novo Nordisk As Azucares y glicopeptidos pegilados enlazados a glicerol.
EP2759302A3 (de) 2006-12-21 2014-11-05 Biokine Therapeutics LTD. 4F-benzoyl-TN14003 kombiniert mit Rituximab für die Verwendung in der Behandlung eines Tumors
BRPI0809670A8 (pt) * 2007-04-03 2018-12-18 Biogenerix Ag métodos para aumentar a produção de célula tronco, para aumentar o número de granulócitos em um indivíduo, para prevenir, tratar e aliviar a mielossupressão que resulta de uma terapia contra o câncer, para tratar uma condição em um indivíduo, para tratar neutropenia e trombocitopenia em um mamífero, para expandir células tronco hematopoiéticas em cultura, para aumentar a hematopoiese em um indivíduo, para aumentar o número de célulars progenitoras hematopoiéticas em um indivíduo, e para fornecer enxerto estável da medula óssea, e, forma de dosagem oral.
EP2162535A4 (de) * 2007-06-04 2011-02-23 Novo Nordisk As O-verknüpfte glykosylierung unter verwendung von n-acetylglucosaminyl-transferasen
MX2009013259A (es) * 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
US7968811B2 (en) * 2007-06-29 2011-06-28 Harley-Davidson Motor Company Group, Inc. Integrated ignition and key switch
CA2697265A1 (en) 2007-08-09 2009-02-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
DE202007018629U1 (de) 2007-08-27 2008-12-24 Biogenerix Ag Flüssigformulierung von G-CSF
HRP20141217T1 (hr) 2007-08-27 2015-02-27 Ratiopharm Gmbh G-csf tekuä†a formulacija
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
WO2009046015A2 (en) * 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
WO2009089396A2 (en) * 2008-01-08 2009-07-16 Neose Technologies, Inc. Glycoconjugation of polypeptides using oligosaccharyltransferases
ES2476690T3 (es) 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
MX2011013459A (es) 2009-06-14 2012-05-08 Biokine Therapeutics Ltd Terapia de peptido para incrementar los niveles de plaquetas.
EP2399572A1 (de) 2010-06-22 2011-12-28 Sandoz AG Langzeitaufbewahrung von nicht-glykosyliertem rekombinantem humanem G-CSF
EP2841084B1 (de) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptid zur verwendung in der behandlung von lungenkrebs
EA201791717A1 (ru) 2012-09-07 2018-03-30 Кохерус Байосайенсис, Инк. Стабильные водные составы адалимумаба
US20180118799A1 (en) 2015-04-13 2018-05-03 National Institute Of Advanced Industrial Science And Technology Cyclized cytokine and method for producing same
EP3322431A2 (de) 2015-07-16 2018-05-23 Biokine Therapeutics Ltd. Zusammensetzungen und verfahren zur behandlung von krebs
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
KR102033920B1 (ko) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4623717A (en) * 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
DE3273597D1 (en) * 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
AU1234383A (en) * 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
CA1297003C (en) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition and method for treating animals
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor

Also Published As

Publication number Publication date
DE68916385T2 (de) 1994-10-13
JP2888969B2 (ja) 1999-05-10
EP0373679A2 (de) 1990-06-20
ES2055001T3 (es) 1994-08-16
AU4668989A (en) 1990-07-10
HK1006812A1 (en) 1999-03-19
EP0373679B1 (de) 1994-06-22
DE68916385D1 (de) 1994-07-28
AU621695B2 (en) 1992-03-19
US5104651A (en) 1992-04-14
CA2005143C (en) 1995-07-11
WO1990006762A1 (en) 1990-06-28
JPH03502808A (ja) 1991-06-27
EP0373679A3 (de) 1991-04-17
CA2005143A1 (en) 1990-06-16

Similar Documents

Publication Publication Date Title
ATE107513T1 (de) Stabilisierte formulierungen mit hydrohoben proteinen.
FI884051L (fi) Menetelmä stabiloitujen humaaniproteiinivalmisteiden valmistamiseksi
GB8610551D0 (en) Polypeptide & protein derivatives
NO180362C (no) Fremgangsmåte for fremstilling av cyklosporinholdige preparater
DK203787A (da) Praeparat til nasal administrering
NO831317L (no) Fremgangsmaate for fremstilling av funksjonelle menneske-urokinase proteiner.
FI91160B (fi) Menetelmä modifioidun ihmisen t-PA-proteiinin valmistamiseksi
FI864552A0 (fi) Human-lysozym.
FI884240A0 (fi) Menetelmä paikalliseen käyttöön tarkoitetun farmaseuttisen valmisteen valmistamiseksi
NO863373D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyre derivater.
FI102282B1 (fi) Menetelmä O-glykosyloidun IGF-1:n valmistamiseksi
NO171396C (no) Fremgangsmaate ved fremstilling av en implantasjon for parenteral administrering
ATE59550T1 (de) Chlorpheniramine therapie.
NO172491C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksan-alkensyre-dervater
FI892254A7 (fi) a-aminoboronihappojohdannaisten käyttö peptidi- ja proteiinilääkeaineiden stabiloimiseen
NO870950D0 (no) Fremgangsmaate for fremstilling av et stabilt injiserbart farmasoeytisk preparat.
NO171295C (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat i form av et biologisk aktivt konjugert protein
AU2846689A (en) Methods for preparing proteins of altered structure
HU907361D0 (en) Process for the production of /n-(gamma-glutamyl)-glycyl/-alanine derivatives and medical preparations containing them
IE880088L (en) Immunoneutering mammalian animals using a peptide conjugated¹with an immunogenic protein
GB8617594D0 (en) Preparation of biologically active proteins
GB8630699D0 (en) Preparation of biologically active proteins
NO883663D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time